PCSK9 and coronary artery disorder: For instance, combinations of statins, inhibitors of HMG-CoA-reductase (HMGCR), with distinct other cholesterol-lowering medications including NPC1L1, PCSK9 and APOB inhibitors have been demonstrated to lower LDLc levels and CAD risk further than statin treatment alone9,10.